Tirzepatide Research: What 2,186 Studies Show (2026) | RetatrutideCompare

Tirzepatide — 2,186 studies indexed on PubMed. Dual GIP / GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, slows gastric emptying, and improves adipocyte fatty-acid handling. Half-life: ~120 hours (~5 days). FDA status: FDA-approved (Mounjaro 2022 for T2D; Zepbound 2023 for chronic weight management; OSA 2024).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Tirzepatide?

There are approximately 2,186 studies indexed on PubMed that mention Tirzepatide (Mounjaro, Zepbound), based on a search last updated 2026-06-18.

Is Tirzepatide FDA-approved?

FDA status: FDA-approved (Mounjaro 2022 for T2D; Zepbound 2023 for chronic weight management; OSA 2024).

How does Tirzepatide work?

Dual GIP / GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, slows gastric emptying, and improves adipocyte fatty-acid handling.

Dual GIP / GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, slows gastric emptying, and improves adipocyte fatty-acid handling.

Reference facts

Also known as
Mounjaro, Zepbound, LY3298176
Category
GLP-1 & Metabolic
Mechanism of action
Dual GIP / GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, slows gastric emptying, and improves adipocyte fatty-acid handling.
Targets
GIPR, GLP-1R
Indications under research or approved
Type 2 Diabetes, Obesity, Obstructive Sleep Apnea (OSA)
Regulatory status (reference entry)
FDA-approved (Mounjaro 2022 for T2D; Zepbound 2023 for chronic weight management; OSA 2024)
Half-life
~120 hours (~5 days)
Sequence
YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS
Sequence notes
39-residue dual GIP/GLP-1 agonist with Aib at positions 2 and 13 (X) and a C20 fatty diacid linker at Lys20.
Molecular weight (Da)
4814
PDB accession
7RTI
Originator / sponsor
Eli Lilly
First reported
2018
Origin
Disclosed by Eli Lilly in 2018 as a unimolecular dual incretin.

Primary References

Explore research articles about Tirzepatide

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.